Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxicities. The results of this study are compared to two similar phase II trials.
Robins
H I
HI
University of Wisconsin Clinical Cancer Center, Madison 53792.
Neuberg
D S
DS
Benson
A B
AB
Pandya
K J
KJ
Tormey
D C
DC
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004341:Drug Evaluation; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D007191:Indazoles; C016371:lonidamine